Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-015306
Filing Date
2024-11-12
Accepted
2024-11-12 16:03:37
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20240930x10q.htm   iXBRL 10-Q 2138886
2 EX-31.1 crvs-20240930xex31d1.htm EX-31.1 11901
3 EX-31.2 crvs-20240930xex31d2.htm EX-31.2 11839
4 EX-32.1 crvs-20240930xex32d1.htm EX-32.1 11821
  Complete submission text file 0001558370-24-015306.txt   8379196

Data Files

Seq Description Document Type Size
5 EX-101.SCH crvs-20240930.xsd EX-101.SCH 47893
6 EX-101.CAL crvs-20240930_cal.xml EX-101.CAL 52263
7 EX-101.DEF crvs-20240930_def.xml EX-101.DEF 207342
8 EX-101.LAB crvs-20240930_lab.xml EX-101.LAB 439405
9 EX-101.PRE crvs-20240930_pre.xml EX-101.PRE 355129
80 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20240930x10q_htm.xml XML 1438078
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 241447870
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)